Autor: "Krop, Ian" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Autorzy:: Hutchinson KE; Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Chen JW; Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Savage HM; Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Stout TJ; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.
Schimmoller F; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.
Cortés J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid & Barcelona, Spain.; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
Dent S; Duke Cancer Institute, Duke University, Durham, NC, USA.
Harbeck N; Breast Center, Department Gynecology and Obstetrics and Comprehensive Cancer Center (CCC) Munich, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.
Jacot W; Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, Montpellier, France.
Krop I; Yale Cancer Center, New Haven, CT, USA.
Trabucco SE; Foundation Medicine, Inc, Cambridge, MA, USA.
Sivakumar S; Foundation Medicine, Inc, Cambridge, MA, USA.
Sokol ES; Foundation Medicine, Inc, Cambridge, MA, USA.
Wilson TR; Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. .; Pokaż więcej
Źródło:: Genome medicine [Genome Med] 2023 Apr 26; Vol. 15 (1), pp. 28. Date of Electronic Publication: 2023 Apr 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Humans ; Female ; Fulvestrant/therapeutic use ; Phosphatidylinositol 3-Kinases/genetics ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Mutation ; Class I Phosphatidylinositol 3-Kinases/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Autorzy:: Miller K; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Cortes J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain and Ramony Cajal University Hospital, Madrid, Spain.
Hurvitz SA; University of California Los Angeles, Los Angeles, CA, USA.
Krop IE; Dana-Farber Cancer Institute, Boston, MA, USA.
Tripathy D; MD Anderson Cancer Center, Houston, TX, USA.
Verma S; Sunnybrook Odette Cancer Centre, Toronto, Canada.
Riahi K; Merrimack Pharmaceuticals, Inc., 1 Kendall Square, Suite B7201, Cambridge, MA, 02139-1670, USA.
Reynolds JG; Merrimack Pharmaceuticals, Inc., 1 Kendall Square, Suite B7201, Cambridge, MA, 02139-1670, USA. .
Wickham TJ; Merrimack Pharmaceuticals, Inc., 1 Kendall Square, Suite B7201, Cambridge, MA, 02139-1670, USA.
Molnar I; Merrimack Pharmaceuticals, Inc., 1 Kendall Square, Suite B7201, Cambridge, MA, 02139-1670, USA.
Yardley DA; Sarah Cannon Research Institute, and Tennessee Oncology, PLLC, Nashville, TN, USA.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2016 Jun 03; Vol. 16, pp. 352. Date of Electronic Publication: 2016 Jun 03.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Research Design*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Doxorubicin/*analogs & derivatives
Immunoconjugates/*therapeutic use
Molecular Targeted Therapy/*methods
Single-Chain Antibodies/*therapeutic use
Breast Neoplasms/pathology ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Female ; Humans ; Immunotoxins/therapeutic use ; Neoplasm Metastasis ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/adverse effects ; Receptor, ErbB-2/antagonists & inhibitors ; Trastuzumab/administration & dosage ; Trastuzumab/adverse effects